[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oncological-outcomes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oncological-outcomes":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,97],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100571259","phase-4-hope-against-cancer-recurrence-in-hcc-100571259",false,"NCT06717919","HOPE Against Cancer Recurrence in HCC","Hypothermic Oxygenated Perfusion (HOPE) Against Cancer Recurrence in HCC Liver Transplantation - International Multicentre Parallel Group Interventional RCT","HOPE4Cancer","Inclusion Criteria:\n\n* Adult recipients (\\>18y), listed for liver transplantation with documented HCC (Liver Imaging Reporting and Data System (LIRADS) 5 lesion in magnetic resonance imaging or computer tomography of the liver or biopsy proven),\n* within up to seven criteria, i.e. HCC with seven as the sum of the diameter of the largest tumour (in cm) and the number of tumours at the time point of liver transplantation,\n* written informed consent for the trial. This also includes patients beyond the up to seven criteria after successful downsizing of the HCC\n\nExclusion Criteria:\n\n* Donation after circulatory death (DCD) liver grafts\n* Combined liver transplants\n* Partial liver transplants\n* Combined or mixed hepatocellular cholangiocarcinoma (cHCC-CCC) or pure cholangiocarcinoma or other malignancies in histopathology of the liver explant\n* Systemic antitumoural medical treatment with checkpoint inhibitors or multikinase inhibitors\n* Post-transplant treatment with mTOR inhibitors\n* Acute and unexpected medical contraindications\n* Pregnancy\n* Cold storage time of \\> 10 hours (both study arms)","ALL","18 Years",{"count":20,"type":21},220,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Liver transplantation is often performed to treat liver cancer, or hepatocellular carcinoma (HCC), in patients with impaired liver function due to cirrhosis. A shortcoming, however, is tumor recurrence after transplantation. Approximately 15 % of patients receiving livers develop recurrence and this depends on the quality of the liver received.\n\nMachine liver perfusion, for example, hypothermic oxygenated liver perfusion (HOPE), which means that the organ is perfused with an oxygen-rich fluid in a cold environment before transplantation, is a novel method to improve the quality of livers before implantation. The standard of care is cold storage without perfusion.\n\nThe objective of this study is to compare the survival after tumor recurrence of patients after liver transplantation for HCC between perfused and not perfused livers. This study's hypothesis is that survival without tumor recurrence is improved when the liver is perfused before implantation.\n\nThe study involves transplant centers worldwide, and adults with HCC waiting for liver transplantation are included. 220 Patients will be recruited within 12 months and then observed for at least 2 years after transplantation. To provide the most valid results, the patients will be randomly allocated to either the organ perfusion group or a control group with standard-of-care cold storage of the organ.",[27,28,29],"Liver Transplantation","HCC","Oncological Outcomes",[31,32,33,34,35],"HOPE","randomised controlled trial","multicentre","hepatocellular carcinoma","liver transplantation","RECRUITING","2025-12-15",{"date":39,"type":40},"2025-12-16","ACTUAL",{"date":42,"type":40},"2025-08-01",{"date":44,"type":21},"2028-01-31",{"name":46,"class":47},"Philipp Dutkowski","OTHER",37,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":56,"targetDuration":58,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":72,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100569332","fertility-protection-for-children-adolescents-and-young-adults-100569332","NCT06692868","Fertility Protection for Children, Adolescents and Young Adults","FeProCAYA","Children, adolescents, young adults with a diagnosis of cancer before the age of 21 years\n\nor\n\nChildren, adolescents, young adults undergoing SCT for a malignant or non-malignant condition before the age of 21 years\n\ntreated at the Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Germany.",{"count":57,"type":21},2000,"20 Years","OBSERVATIONAL","This study focuses on improving fertility preservation and long-term care for children, adolescents, and young adults (CAYA) undergoing cancer treatments or stem cell transplantation. These treatments can harm fertility, and ensuring that patients receive the right support and follow-up care is critical.\n\nThe main study goals are:\n\n1. Understanding Fertility Risks: Researchers aim to identify factors that predict fertility problems after cancer treatments, such as the type of therapy, hormone levels, body composition, or genetic predispositions.\n2. Addressing Patient and Family Needs: The program will explore the concerns, needs, and challenges faced by young patients and their parents regarding fertility. It will also examine how these issues affect their quality of life.\n3. Improving Clinical Care: Current practices in fertility preservation and counseling will be studied to identify gaps and improve care structures.\n\nTo achieve these goals, the program will:\n\n* Create a database to collect and analyze medical data from patients before, during, and after cancer treatments.\n* Study the prevalence and long-term effects of fertility problems in young patients.\n* Document medical interventions like fertility preservation methods (e.g., freezing eggs or sperm) and treatments for late effects.\n* Assess patients' and families' fertility-related quality of life and their informational needs.\n\nUltimately, the project aims to establish an interdisciplinary center to support fertility preservation and improve the quality of care for young patients facing cancer and its treatments.",[62,63,29,64,65,66,67,68,69,70,71],"Stem Cell Transplant","Stem Cell Transplantation","Oncological Patients","Oncological Children","Fertility","Fertility Protection","Endocrinological Late-effects","Paediatric Oncology","CAYA","Survivors",[54,73,74,75,76,77,78,79,80,81,82,83,84,85,86,70],"Fertility protection","Endocrinological follow-up after oncological disease","children","fertility","adolescents","young adults","TYA","teenagers and young adults","paediatric oncology","follow-up care","endocrinological late-effects","survivors","stem cell transplant","stem cell transplantation","2025-01-13",{"date":89,"type":40},"2025-01-16",{"date":91,"type":40},"2024-12-09",{"date":93,"type":21},"2044-11",{"name":95,"class":47},"University of Ulm",1,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":105,"minAge":18,"maxAge":106,"enrollmentInfo":107,"targetDuration":109,"studyType":59,"phases":4,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":127},"100537548","national-robotics-assisted-radical-prostatectomy-database-100537548","NCT06279260","National Robotics-Assisted Radical Prostatectomy Database","National Robotics-Assisted Radical Prostatectomy Database: Exploring Learning Curves and Long Term Surgical, Oncological and Patient Reported Outcome Measures (PROMS)","RASOR","Inclusion Criteria:\n\nTo be eligible to participate in this database, an individual must meet all of the following criteria:\n\n1. Individuals who consent to participate,\n2. within the age range of 18 to 90 years,\n3. confirmed diagnosis of localized prostate cancer (PCa)\n4. patients receiving medical attention at hospitals engaged in collaborative efforts with the designated database.\n\nExclusion Criteria:\n\n1. Participants are not eligible to take part in the database:\n2. Individuals who have not undergone robotic surgery for prostatectomy or TP biopsy. ,\n3. without a diagnosis of prostate cancer or\n4. who decline to provide consent for the collection of their health information\n5. Under the age of 18 years.","MALE","90 Years",{"count":108,"type":21},10000,"5 Years","In Australia, nearly 70 men are diagnosed with Prostate cancer every day. Prostate removal (Radical Prostatectomy) is the proven treatment option to control cancer spread. Most of the prostate removal surgeries are done using robots. Robotic assisted prostate removal surgeries have been invented to minimise the risk of side effects post-surgery. Doctors prefer the robots over open surgery as there are benefits to patients (shorter hospital stays, lesser blood loss and better quality of life) and surgeons (better dexterity, improved field of vision and less pain). However, the cost of the robot outweighs the benefits at present and there is very less information concerning the long-term outcomes for patients.\n\nStudies conducted so far are small scale studies and the results from these studies cannot be generalized to the population at large in Australia. So, there is need for a largescale study that will look at the long-term outcomes and the factors that impact robotic surgeries across the metropolitan and rural hospital sectors.\n\nHence, this comprehensive database has been setup to collaborate with major hospitals, across metropolitan and rural areas in Australia. Through this database, researchers will be able to explore the diagnostic pathway for Prostate cancer and understand the long-term benefits of robotic surgery through patient reported questionnaires. Outcomes from this database will also help compare the quality of care against other powerhouses of robotic surgery.\n\nEventually, the database aims to standardize diagnostic pathways and clinical notes that are the same across different hospitals conducting robotic-assisted surgeries for Prostatectomy and improve care for prostate cancer patients across the country.",[112,113,114,115,29,116,117],"Database","Prostate Cancer","Robotic-assisted Radical Prostatectomy","Surgical Outcomes","Patient Reported Outcome Measures","Learning Curve","2024-08-22",{"date":120,"type":40},"2024-08-26",{"date":122,"type":40},"2024-07-01",{"date":124,"type":21},"2050-12",{"name":126,"class":47},"Melbourne Health",8]